Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: A study in the French PharmacoVigilance Database

British Journal of Clinical Pharmacology

Volumn 74, Issue 1, 2012, Pages 201-204

  Moulis, Guillaume ^a,b,c   Sommet, Agnès ^a,b,c   Durrieu, Geneviève ^a,c   Bagheri, Haleh ^a,c   Lapeyre Mestre, Maryse ^a,b,c   Montastruc, Jean Louis ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

'serious' adverse drug reactions; Adverse drug reactions; Pharmacovigilance; Spontaneous reporting

Indexed keywords

BETA INTERFERON; CELECOXIB; ESOMEPRAZOLE; ETANERCEPT; ETIRACETAM; GALANTAMINE; OXCARBAZEPINE; PEGINTERFERON ALPHA2A; PIOGLITAZONE; PRESCRIPTION DRUG; RISEDRONIC ACID; ROSIGLITAZONE; TIBOLONE; TRASTUZUMAB; VERTEPORFIN;

ADVERSE OUTCOME; ARTICLE; DATA BASE; DRUG SURVEILLANCE PROGRAM; DRUG USE; FRANCE; HOSPITAL; HUMAN; PRIORITY JOURNAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ATTITUDE OF HEALTH PERSONNEL; DATABASES, FACTUAL; DRUG TOXICITY; FRANCE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE; TIME FACTORS;

EID: 84862144289     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04185.x     Document Type: Article

References (18)

1. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 2004; 57: 127-34.
2. Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 2008; 22: 127-40.
3. Royer RJ. Mechanism of action of adverse drug reactions: an overview. Pharmacoepidemiol Drug Saf 1997; 6: (Suppl. 3): S43-50.
4. Stephen M. Introduction. In: Stephens' Detection of Adverse Drug Reactions, 6th edn., eds Talbot J, Walter P. Chichester: John Wiley & Sons, Ltd, 2004; 14.
5. Weber J. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Advances in Inflammatory Research, eds Rainsford KD, Velo GP. New York: Raven Press, 1984; 1-7.
6. Haramburu F, Bégaud B, Moride Y. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. Br J Clin Pharmacol 1997; 44: 299-301.
7. Hasford J, Goettler M, Munter K-H, Müller-Oerlinghausen B. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 945-50.
8. Montastruc J-L, Sommet A, Lacroix I, Olivier P, Durrieu G, Damase-Michel C, Lapeyre-Mestre M, Bagheri H. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 2006; 73: 629-32.
9. Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL. French pharmacovigilance database system: examples of utilisation. Therapie 1995; 50: 557-62.
10. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
11. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111-8.
12. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109-17.
13. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004; 24: 743-9.
14. Brodovicz K, Sharrar R, Hostelley L. The Weber effect - is it real? Pharmacoepidemiol Drug Saf 2001; 10: S138.
15. de Graaf L, Fabius MA, Diemont WL, van Puijenbroek EP. The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles. Pharm World Sci 2003; 25: 260-3.
16. McAdams MA, Governale LA, Swartz L, Hammad TA, Dal Pan GJ. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Pharmacoepidemiol Drug Saf 2008; 17: 882-9.
17. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 2001; 24: 233-7.
18. Hartnell NR, Wilson JP, Patel NC, Crismon ML. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother 2003; 37: 1387-91.